Anthropic's IPO Filing Reveals Its Unusual Governance Plan
Anthropic's IPO filing lays out a board structure built to keep control with its founders and a trust focused on humanity's benefit, even as outside investors come in. The setup gives the seven co-founders 50.1% voting power on certain matters and sets up a staggered board that goes against current corporate governance norms.
- Anthropic's seven co-founders hold 50.1% voting power over certain matters, and their supervoting stock extends to electing the remaining directors and shareholder proposals.
- A long-term benefit trust, currently chaired by Neil "Buddy" Shah, controls a special Class T stock that lets it elect a board majority, and the filing includes provisions to keep directors bound to the public benefit purpose if that stock changes hands.
- Once the co-founders' supervoting stock expires, the board splits into three groups on three-year terms, a structure once used to resist hostile takeovers and at odds with the annual elections most major US companies now use.
Anthropic's IPO filing lays out a governance structure built to keep control with its founders and a long-term trust, even as public investors come in. The seven co-founders, including CEO Dario Amodei and his sister Daniela Amodei, hold 50.1% of voting power over certain matters. An independent trust, chaired by global health leader Neil "Buddy" Shah, controls a majority of board seats through a special "Class T" stock. The company expects a valuation around $1.5 trillion, which would make it the most highly valued public benefit corporation in the world. That status under Delaware law requires the company to weigh a broader public good against shareholder returns.
The filing also details how the company plans to outlive its founders. Once most co-founders leave and their "Class F" supervoting stock disappears, the board will split into three equal groups serving staggered three-year terms, a structure more often associated with the US Senate and with defenses against hostile takeovers. That runs against the modern trend among major US companies toward annual elections for all directors. Anthropic has also planned for the case where the Class T stock falls into the wrong hands: directors would still have to follow provisions tied to the company's public benefit purpose. Because the trust effectively controls the board, Anthropic qualifies as a "controlled company" under Nasdaq rules, which exempts it from requirements like an independent nominating committee. It is using that exemption to seat Daniela Amodei on that committee.
Day-to-day oversight sits with a safety and risk committee made up of Novartis CEO Vas Narasimhan and former Trump White House official Chris Liddell, while Reed Hastings serves as lead independent director. The co-founders remain central through an entity called "Founder LLC," which will hold the second-largest say in board elections after the trust. For investors, the practical upshot is that they buy into a company whose board they cannot easily influence, with the founders and trust deciding who governs. Anthropic declined to comment on the filing.